Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of Ambrisentan in PAH
NCT00046319Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started Sep 2002; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00046319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046319.